Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RBMS3 antisense RNA 3 (RBMS3-AS3) is a long non-coding RNA transcribed antisense to the RBMS3 gene, and is not translated into protein. RBMS3-AS3 has been implicated in cancer biology, especially as a tumor suppressor in prostate cancer, where it inhibits proliferation, migration, invasion, and tumorigenesis by acting as a microRNA-4534 sponge. Its upregulation leads to increased expression of VASH1, an anti-angiogenic protein. While its main role appears regulatory at the transcript level, especially via competing endogenous RNA networks, more research may clarify its function in other diseases or pathways.
Acts as a ceRNA/microRNA sponge for miR-4534, relieving inhibition of VASH1 (vasohibin 1), thereby inhibiting cancer cell progression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RBMS3 antisense RNA 3 (RBMS3-AS3).